Friday , October 28 2016
Letairis 1000x128 45448

Only Letairis + tadalafil unlocks the combination of ambition

Only Letairis + tadalafil unlocks the outcomes of ambition

For the treatment of pulmonary arterial hypertension (PAH, WHO Group 1)

Letairis + tadalafil initial combination therapy is approved to

Reduce the risk of disease progression

Reduce the risk of hospitalization for worsening PAH

Improve exercise ability

The study establishing effectiveness included predominantly patients
with WHO Functional Class II–III symptoms...

...and etiologies of idiopathic or heritable PAH (58%) or PAH
associated with connective tissue diseases (36%).2

Click Here to learn more about the AMBITION trial.

Important Safety Information

Letairis ambrisentan 5 mg and 10 mg Tablets Please click here for full
Prescribing Information,
including BOXED WARNING.

Recent Posts